Advertisement Chinese Regulatory Changes for Human Serum and Plasma Exports Trigger Potential Delays - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Whitepapers

Chinese Regulatory Changes for Human Serum and Plasma Exports Trigger Potential Delays

Researchers conducting or planning to conduct clinical trials in China should be aware of new regulatory changes that specifically affect export shipments of human serum and plasma from China and the delays that the new administrative process may create. This free white paper includes a list of these major changes associated with the new regulations.

Download whitepaper

Enter your details to get your free whitepaper:


Submit

I have read and accept the terms and conditions and privacy policy.

receive-email We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.

third-party If you would like to hear from carefully selected third party companies, check this box.

company-follow Follow this company to receive notifications when they update.


More from World Courier